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Abstract:
Purpose:
The aim was to report the aqueous humor moxifloxacin concentration and proteome profile of an individual with bilateral uveitis-like
syndrome with pigment dispersion.
Methods:
Multiple reactions monitoring mass spectrometry quantified the aqueous concentration of moxifloxacin in the affected individual.
Shotgun  proteomic  analysis  performed  via  liquid  chromatography  tandem mass  spectrometry  (LC-MS/MS)  defined  the  protein
profile in the affected individual and unaffected control samples.
Results:
Moxifloxacin was present at higher than expected levels in aqueous humor 18 days following oral administration. One-third of the
proteins were identified by significantly lower spectral counts in the aqueous of the individual with moxifloxacin associated uveitis
compared to the unaffected control.
Conclusion:
Moxifloxacin was detected in aqueous humor 18 days following the completion of oral administration. These results suggest that
moxifloxacin toxicity may be responsible for the uveitis-like syndrome with pigment dispersion syndrome induced by moxifloxacin
therapy.
INTRODUCTION
Fluoroquinolones are a broad spectrum antibiotic class indicated for the treatment of bacterial infections including
acute exacerbation of chronic bronchitis, complicated intra-abdominal abscess, community acquired pneumonia, acute
sinusitis and uncomplicated skin infections. Fluoroquinolone antibiotics inhibit DNA gyrase activity, thereby disrupting
bacterial DNA replication and transcription. Adverse drug  reactions  unique  to  quinolones  include  tendinitis,  tendon
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rupture,  peripheral  neuropathy and diplopia.  Uveitis  was not  reported in premarketing trials  in  the package inserts.
Following the initial report of bilateral panuveitis associated with oral moxifloxacin therapy in 2004, there have been
additional  reports  of  a  bilateral  uveitis-like  syndrome  with  anterior  chamber  pigment  dispersion  and  iris
transillumination  [1  -  3].
We report the moxifloxacin concentration and proteomic analysis of aqueous humor obtained during the acute phase
of  bilateral  pigment  dispersion  with  elevated  intraocular  pressure  and  subsequent  development  of  diffuse  iris
transillumination.
The  goals  of  this  study  were  to  establish  if  moxifloxacin  is  sequestered  in  aqueous  humor  following  systemic
administration and to determine whether the aqueous proteome is altered by the condition. While this phenomenon has
been  described  clinically,  the  full  characterization  of  aqueous  humor  to  corroborate  the  observation  has  not  been
published. A two-pronged approach using mass spectrometry was employed to perform both relative quantification of
moxifloxacin, and protein content within aqueous of affected and control eyes.
METHODS
A 71 year old Caucasian female developed bilateral painful red eyes with photophobia 14 days following inpatient
treatment  for  pneumonia  with  moxifloxacin  (Bayer  HealthCare  Pharmaceuticals,  San Francisco,  CA) 400mg daily.
There  was  no  past  history  of  uveitis,  glaucoma  or  pigment  dispersion.  Best  corrected  visual  acuity  was  20/200
bilaterally  (LogMAR 1.00).  Microcystic  corneal  edema  secondary  to  elevation  of  intraocular  pressure  greater  than
40mmHg in both eyes developed despite maximal topical glaucoma therapy and oral acetazolamide 500 mg twice daily.
Moxifloxacin associated uveitis was suspected due to bilateral, extensive pigment dispersion present in the anterior
chamber. Anterior chamber paracentesis for diagnostic and therapeutic purposes was performed 18 days following the
last oral dose of moxifloxacin. A peripheral corneal paracentesis incision was made with a sterile 15 degree steel blade
and 0.15 mL of aqueous fluid was harvested from the right eye (OD) and 0.27 mL was harvested from the left eye (OS)
using a blunt 27 gauge cannula. Aqueous humor samples were stored frozen at -80 °C and transported on dry ice for
quantification of moxifloxacin concentration and proteome analysis.
Urgent bilateral glaucoma drainage device surgery was required due to intraocular pressure elevation greater than
40mmHg  despite  maximal  medical  therapy.  Pigment  dispersion  persisted  for  more  than  one  year  with  subsequent
development of bilateral iris transillumination and cataracts in both eyes. Bilateral posterior synechiae were observed at
the time of cataract surgery and the early post-operative course was complicated by formation of fibrin in the anterior
chamber.
One unaffected patient consented to harvest of aqueous humor via corneal paracentesis immediately prior to cataract
surgery (control). Written informed consent was obtained from each subject. This study was performed in accordance
with the Declaration of Helsinki.
Mass Spectrometry Sample Preparation: Moxifloxacin quantification was performed for each of the three samples
(OS, OD and control). Proteins were precipitated using 4 volumes of cold (-20 °C) methanol. Starting volumes isolated
from patients were: 150 µL control, 150 µL OD and 270 µL OS. Samples were incubated for 30 min at -80 °C and
centrifuged for 10 min at 10000 rpm at 4 °C. Supernatants were dried and re-suspended in TQ-S Buffer A (0.1% formic
acid  in  water)  for  multiple  reaction  monitoring  (MRM)  mass  spectrometry  analysis.  The  protein  pellets  were  then
analyzed with LTQ shotgun proteomic analysis.
Protein pellets were re-suspended in 10 mM ammonium bicarbonate (ambic) and quantified by micro bicinchoninic
acid assay (mBCA). The total proteins in the samples are as follows: Control (11.3 µg), OD (32.8 µg) and OS (177.7
µg).  To  normalize  the  protein  samples,  only  10  µg  were  used  in  the  protein  analysis.  Samples  were  digested  with
trypsin  via  in-solution  protocol  as  previously  described  [4].  Briefly,  samples  were  denatured  in  6  M  guanidine
hydrochloride, reduced with 10 mM DTT and alkylated with 100 mM iodoacetamide. After overnight micro-dialysis in
10  mM ammonium bicarbonate,  the  samples  were  digested  with  trypsin  (1:50,  trypsin:sample)  in  10% acetonitrile
(ACN) overnight at 37 °C. Digests were dried and re-suspended in LTQ loading buffer (3% ACN and 0.1% formic acid,
in water). All digests were performed in de-plasticized tubes to reduce plastic polymer contamination.
Relative  Quantification  of  Moxifloxacin  by  Multiple  Reaction  Monitoring  (MRM)  Mass  Spectrometry:  All  the
analyses were performed on an LC-MS/MS system consisting of Waters nanoACQUITY UPLC coupled to a Waters
Xevo  TQ-S  mass  spectrometer  fitted  with  TRIZAIC  source.  The  instrument  was  operated  in  positive  electrospray
ionization mode using MassLynx V4.1 SCN810 (Waters, Milford, MA). Chromatography was performed on 150 μm ×
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50 mm TRIZAIC™ nanoTile packed with BEH C18 1.7 μm. Injections were 2 µl using partial loop mode. The initial
solvent composition was 90% A (0.1% formic acid in water) and 10% B (0.1% formic acid in methanol). The mobile
phase gradient was: 10-55% B from 0.25-1 min, 55-95% B from 1-15.5 min, 95-10% B from 15.5-16 min, and a hold at
10% B from 16-20 minutes. The flow rate was 3.06 µL/min and the column was maintained at 46 oC. The cone voltage
was static at 50 V. The capillary voltage was 3.2 kV, source temperature was 100 oC, source offset was 50 V, and the
collision gas was argon. Dwell time for all compounds was 0.830 s. Moxifloxacin parent mass to charge ratio (m/z) was
determined to be 401.175. The two daughter ions monitored were m/z 358 and m/z 384, corresponding to the loss of
CO2 and H20 respectively [5]. Collision energy necessary to generate the daughter species was determined to be 20 V
(for the loss of CO2) and 30 V (for the loss of H20). Patient samples were randomized and injected in triplicate.
MRM Data Analysis: Quantification of patient samples was done using linear regression against a standard curve in
TargetLynxTM (Waters, Milford, MA). Curves were generated from the ophthalmic solution moxifloxacin in 0.5% HCI
(Vigamox, Alcon, Fort Worth TX) utilizing the control patient sample as a representative background matrix. Eight
concentrations ranged from 0.1 – 1000 nmol/ µL, and each sample was injected in triplicate from which one regression
equation was generated per ion Fig. (1). The concentration of each daughter ion in Control, OD and OS sample was
calculated based on this data (Table 1). Peak identification was performed using MassLynx software version 4.1. Upon
examination and standardization of the peaks, the transition results were exported to ExcelTM (Microsoft, Redmond WA)
for calculation of calibration curves (R2 values for each curve are shown in (Table 1), as well as determination of limits
of detection (LOD) and quantitation (LOQ) for each transition [6, 7]. LOD = 3.3 (SD/S) and LOQ = 10 (SD/S), where
SD is the standard deviation of y values and S is the slope of the calibration curve. SD of y was calculated in ExcelTM
using the LINEST function (Table 2).
Fig. (1). Calibration curve for both transitions of moxifloxacin determined from response in matrix. See (Table 1) for results.
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Table 1. Results of calibration curve calculation and determination of limits of detection and quantitation.
Ion R2 SD of y LOD (ng) LOQ (ng)
358.00 0.98 51.42 25.83 86.11
384.00 0.97 63.29 12.34 41.13
Table 2. Concentration of moxifloxacin in the patient samples. The transition ion m/z 358 was well above both the LOD and
LOQ in both of the samples and therefore was used to quantitate the amount of moxifloxacin in the original more dilute
samples. The transition ion m/z 384 was below the LOQ and could not be used to quantitate the amount of moxifloxacin,
however since the concentration was above that of the LOD we can use it as a confirmatory ion, enhancing the confidence of
the detection.
Sample Ion Role calculated concentration injected (ng/µL) concentration of moxifloxacin in sample (ng/µL)
OD 358.00 Quantitation 268.32 44.72
OD 384.00 Confirmation 20.73 below LOQ
OS 358.00 Quantitation 101.33 93.82
OS 384.00 Confirmation 27.38 below LOQ
Mass Spectrometry of tryptic peptides. LC-MS/MS methods for proteomic analysis were previously published [7].
All  samples were injected at  a concentration of approximately 500 ng/µL. Peptides were purified and concentrated
using  an  on-line  enrichment  column  (Agilent  Zorbax  C18,  5  µm,  5×0.3  µm  column,  Agilent  1100  nanoHPLC,).
Subsequent chromatographic separation was performed on a reverse phase nanospray column (Zorbax C18, 5 µm, 75
µm ID × 150 mm column). Samples were eluted into an LTQ linear ion trap (Thermo Scientific, Waltham, MA) using a
flow rate of 300 nL/min with a linear gradient of acetonitrile. Mass spectra were recorded over a m/z range of 200–2000
Da  using  a  dynamic  exclusion  limit  of  2  MS/MS  spectra  of  a  given  mass  for  30  s  (exclusion  duration  of  90  s).
Compound lists of resulting spectra were generated using BioworksTM 3.0 software (Thermo Scientific) with intensity
threshold of 5,000 and 1 scan/group. All the samples were run in triplicate.
Table 3. List of proteins identified in the control and two patient samples. Three technical replicates were performed for each
biological  sample  and  the  spectral  counts  determined  for  each  is  listed.  A  single  protein  which  matched  to  the  reverse
database (in bold) is responsible for the FDR rate of 3%.
# Identified Proteins (33)
Samples and Technical Replicates
Control OD OS
1 2 3 1 2 3 1 2 3
1 Serum albumin 1065 1008 1158 1157 1412 1049 1418 1253 1062
2 Serotransferrin 197 241 231 99 125 47 112 115 41
3 Alpha-1-antitrypsin 13 9 12 24 23 17 23 16 20
4 Ig gamma-1 chain C region 22 31 17 11 12 8 11 8 3
5 Prostaglandin-H2 D-isomerase 28 37 29 12 8 1 3 11 2
6 Transthyretin 15 16 12 24 25 7 20 13 7
7 Ig kappa chain C region 13 22 24 8 7 4 16 6 2
8 Alpha-1-acid glycoprotein 1 9 9 9 20 14 8 14 10 7
9 Hemopexin 7 7 7 22 18 8 9 6 1
10 Ig lambda-2 chain C regions 15 17 13 12 8 1 15 16 6
11 Complement component C4B 8 8 8 8 7 4 5 9 3
12 Pigment epithelium-derived factor 16 17 14 3 5 1 5 3 2
13 Vitamin D-binding protein 2 4 4 6 6 6 8 10 5
14 Ceruloplasmin 7 8 12 2 3 1 1 1 1
15 Alpha-1B-glycoprotein 1 7 8 5 4 3 5 9 6
16 Isoform 2 of Clusterin 14 5 4 8 7 2 4 6 3
17 Apolipoprotein A-I 3 0 5 8 3 4 5 7 3
18 F-box/SPRY domain-containing protein 1 0 1 0 2 2 1 0 0 0
19 Zinc-alpha-2-glycoprotein 6 3 6 2 3 2 3 4 1
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# Identified Proteins (33)
Samples and Technical Replicates
Control OD OS
1 2 3 1 2 3 1 2 3
20 Hemoglobin subunit beta 7 9 9 0 0 0 2 0 0
21 Alpha-1-antichymotrypsin His-Pro-less 5 2 3 10 11 1 4 3 3
22 Retinol-binding protein 3 5 3 8 1 1 0 2 1 1
23 Complement C3 1 0 0 4 5 1 2 1 3
24 Ig gamma-2 chain C region 13 11 16 0 0 0 0 0 0
25 Ig gamma-4 chain C region 8 10 13 0 0 0 0 2 0
26 Apolipoprotein A-II 3 2 2 2 4 2 0 0 2
27 Haptoglobin 1 1 2 1 2 1 3 1 1
28 Alpha-2-HS-glycoprotein chain A 0 1 1 3 1 4 0 0 0
29 Antithrombin-III 0 0 0 2 1 3 0 0 0
30 Ig gamma-3 chain C region 12 11 6 0 0 0 0 0 0
31 Gelsolin 0 0 3 0 0 0 0 0 0
32 Protein shisa-7 0 0 0 0 2 0 0 0 0
33 Dickkopf-related protein 3 0 3 0 2 1 0 0 0 1
Database searching and Criteria for Protein Identification. All tandem mass spectra (.raw files) were extracted by
LCQ_DTA.exe (Thermo Scientific) for subsequent loading into the Mascot (Matrix Science, London, UK; version:
2.3.02  Mascot  MS/MS  search  engine  or  into  Bioworks  Browser  (version  3.3.1  SP1)  for  subsequent  analysis  with
Sequest  (Thermo  Finnigan,  San  Jose,  CA;  version  SRF  v.27,  rev.  11)  and  X!  Tandem  (version  CYCLONE
2010.12.01.1)  [8].  All  three  search  engines  were  used  to  query  the  Universal  Protein  Resource  (UniProt)  human
database (created on 11/26/12) composed of 169776 entries including reverse proteins for false discovery calculation.
All searches were performed assuming trypsin digestion, with a fragment ion mass tolerance of 1.5 Da, a parent ion
tolerance of  2.5  Da.  Oxidation of  methionines  (+16)  and iodoacetamide derivative of  cysteine residues  (+57)  were
specified as variable modifications.
All data was compiled using Scaffold (version 3.6.1, Proteome Software Inc., Portland, OR) in order to validate
MS/MS  based  peptide  and  protein  identification.  Peptide  identifications  were  accepted  if  established  using  the
following scores: Mascot: Ion Identity: 0, Ion score +1, +2 and +3 all at 55; Sequest: DeltaCn: 0.06, XCorr +1, +2 and
+3 at  1.05,  2.1  and 3.15,  respectively;  X! Tandem: -Log(E-Value):  2.  Protein identifications were only accepted if
established at greater than 99% probability and contained at least two identified peptides. Protein probabilities were
assigned by the Protein Prophet algorithm [9]. False discovery rate (FDR) for proteins was calculated to be 3% at the
protein  level  and  0.1%  at  the  peptide  level  (Table  3).  Raw  and  searched  data  files  are  accessible  via
http://proteomecentral.proteomexchange.org/cgi/GetDataset.
RESULTS
MRM method development on ophthalmic moxifloxacin solution afforded monitoring of the parent compound (m/z
401.175) and upon fragmentation, two daughter species, m/z 358 and m/z 384, corresponding to loss of CO2 and H20
respectively.  Relative  quantification  of  clinical  samples  was  based  on  dosage  response  curves  generated  from this
solution Figs. (1 and 2).
As expected, the control sample did not contain detectable levels of moxifloxacin. The transition ion m/z 358 was
detected well above both the LOD and LOQ in aqueous humor samples from both affected eyes. This data was used to
quantitate the amount of moxifloxacin in these samples. The transition ion m/z 384 was below the LOQ and could not
be used to quantitate the amount of moxifloxacin, however, since the concentration was above that of the LOD we can
use it as a confirmatory ion, enhancing the confidence of the detection. The levels determined by this technique, while
not absolute, are consistent with the level of moxifloxacin calculated to be present roughly 2.5 days post administration,
rather  than  18  days,  based  on  the  previously  reported  intraocular  concentration  and  pharmacokinetics  of  orally
administered  moxifloxacin.
The protein fraction of aqueous was analyzed by shotgun tandem mass spectrometry. Thirty-three proteins were
confidently in aqueous of affected eyes and 32 proteins in an unaffected control eye. Ten proteins were significantly
reduced in affected eyes compared to control (Table 4).
(Table ?) contd.....
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Fig. (2). Slit lamp photomicrograph demonstrating progressive depigmentation of the iris stroma of the right eye (Panel A photo
taken in 2012 and Panel B taken in 2013) in an individual following topical administration of moxifloxacin.
Table 4. List of proteins found to be reduced significantly by ANOVA in the patient samples compared to the control.
Identified Proteins Accession Number ANOVA Test (P-Value)
Ig gamma-1 chain C region IGHG1_HUMAN 0.022
Retinol-binding protein 3 RET3_HUMAN 0.016
Serotransferrin TRFE_HUMAN 0.011
Prostaglandin-H2 D-isomerase PTGDS_HUMAN 0.0028
Ig gamma-3 chain C region IGHG3_HUMAN 0.0027
Ceruloplasmin CERU_HUMAN 0.0014
Pigment epithelium-derived factor PEDF_HUMAN 0.00053
Hemoglobin subunit beta HBB_HUMAN 0.000059
Ig gamma-4 chain C region IGHG4_HUMAN 0.00004
Ig gamma-2 chain C region IGHG2_HUMAN 0.0000056
DISCUSSION
More  than  50  cases  of  bilateral  simultaneous  uveitis-like  syndrome  with  pigment  dispersion  and  iris
transillumination  have  been  reported  following systemic  administration  of  moxifloxacin  or  levofloxacin  [1,  2,  10].
Because iris transillumination is frequently observed in the light colored irides of patients with herpetic uveitis, some
patients with uveitis following oral fluoroquinolone therapy were treated with oral anti-viral therapy without favorable
effect  on  the  course  of  the  condition  [10].  Furthermore,  qualitative  polymerase  chain  reaction  analysis  of  aqueous
humor  obtained  from 4  of  5  patients  did  not  demonstrate  amplification  of  DNA for  herpes  simplex,  herpes  zoster,
cytomegalovirus or Epstein-Barr virus genomes [2, 10]. One individual with prior history of uveitis had PCR evidence
of HSV viral genome in aqueous [2]. To our knowledge, none of the previously reported individuals were tested for, nor
exhibited findings typical of, human herpes virus 6 (HHV6) associated uveitis, i.e. panuveitis in association with optic
papillitis; however, it appears unlikely that a virus in the herpes family is the causative agent for the condition based on
disparity between the clinical signs and lack of therapeutic response to empiric antiviral therapy.
Large, retrospective cohort studies have yielded conflicting results regarding the risk of uveitis and the use of oral
fluoroquinolones. In one cohort, oral administration of fluoroquinolones confered an adjusted relative risk of 3.53 for
development of uveitis within the subsequent 30 days [11]. The relative risk of uveitis was also increased in patients
receiving oral macrolide and beta lactam antibiotics. The authors postulated systemic infectious disease, rather than the
antibiotic administered, might be the cause of uveitis observed in these cases [11]. A second case-control study reported
similar adjusted rate ratios of 2.98, 1.96 and 1.26 for the development of uveitis in first time users of moxifloxacin,
ciprofloxacin  and  levofloxacin,  respectively,  compared  to  age  and  gender  matched  controls  [12].  A  third  study
A
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calculated the hazard of uveitis development was not elevated after a fluoroquinolone prescription compared with the
hazard of uveitis following a beta-lactam prescription and identified the risk for uveitis-associated systemic illnesses as
a potential source of bias in the previous studies [13].
Tugal-Tutkin termed the condition bilateral acute iris transillumination (BAIT) and postulates it may be caused by
an emerging respiratory pathogen rather than an adverse drug reaction because antibiotic therapy was not known to
precede  the  condition  in  38%  of  26  cases  [14].  Prior  moxifloxacin  therapy  was  identified  in  35%  of  cases  and
antibiotics other than flouroquinolones were identified in 27% of cases. Tugal-Tutkin also described bilateral acute
depigmentation  of  the  iris  (BADI),  in  contrast  to  BAIT  which  preferentially  affects  the  iris  pigment  epithelium,  a
condition with predilection for loss of iris stromal pigmentation which is reversible in some cases [15]. BAIT may be a
severe,  irreversible  form  of  BADI.  Unilateral  depigmentation  of  the  iris  was  observed  by  one  the  authors  (PD)
following  ipsilateral  topical  moxifloxacin  therapy  in  an  individual  from  India  suggesting  that  local  moxifloxacin
therapy may rarely produce similar ocular findings (Fig. 2A, B).
Orally  administered  moxifloxacin  crosses  the  blood  ocular  barrier  of  non-inflamed  human  eyes  and  achieves
concentrations of 1.58 +/-0.80µg/mL within 4 hours of administration of a single 800mg dose [16]. Rabbit studies of
intravitreal moxifloxacin clearance report a vitreous half-life of 1.72 hours [17]. Because the serum half-life of orally
administered moxifloxacin is 12 hours, moxifloxacin should be undetectable in human serum 5 days following oral
administration [18]. Assuming human pharmacokinetics is comparable to the rabbit model, moxifloxacin should be
undetectable  in  vitreous  humor  within  12  hours  of  a  single  intravitreal  injection.  Although  aqueous  clearance  of
antibiotics and other pharmaceuticals is typically more rapid than vitreous clearance in animals and humans, vitreous
clearance of  moxifloxacin may be slower in  humans than animals.  If  we assume elimination of  moxifloxacin from
human aqueous is equivalent to first order elimination of moxifloxacin from rabbit vitreous then the concentration of
moxifloxacin present in aqueous on the last day of systemic administration can be calculated as 3023 grams using the
formula:
Initial concentration = Final concentration / 2n where n = half life
This  amount  vastly  exceeds  the  total  systemic  dose  (4  grams)  the  patient  received.  There  are  several  possible
explanations for persistent moxifloxacin detected in aqueous humor 18 days following oral administration. Antibiotic
clearance is generally believed to be delayed in inflamed eyes. Supra-therapeutic levels might result despite following
recommended dosing due to impaired drug metabolism and elimination with resultant toxicity and shedding of iris and
ciliary  body  pigment  epithelium.  Affected  individuals  may  have  a  heretofore  unrecognized  enzyme  deficiency
impairing  moxifloxacin  elimination.  To  our  knowledge,  only  one  case  exhibited  co-morbid  systemic  symptoms  of
moxifloxacin toxicity [10]. Alternatively, moxifloxacin clearance from the anterior chamber may be impaired by the
tremendous  amount  of  pigment  dispersion  blocking  aqueous  egress  through  the  trabecular  meshwork.  Serum
moxifloxacin concentration was not determined in our patient nor reported in any prior publications, thus it is not clear
whether persistent elevation of moxifloxacin is a local or systemic phenomenon
Knape et al. observed only phakic individuals have been reported to develop BAIT and suggest that drug may be
trapped behind the iris by posterior synechiae which they confirmed via optical coherence tomography in one patient
[19]. Not all patients with the condition have posterior synechiae [10]. One would expect the pupil would need to be
completely secluded in order to sequester drug or aqueous in the posterior chamber. Pupil seclusion should result in iris
bombe and secondary angle closure but this has not been observed. Conversely, some patients have abnormally deep
anterior chambers with reverse papillary block or iris concavity configuration similar to the typical pigment dispersion
patient [3, 18].
Intraocular  injection  of  moxifloxacin  is  advocated  for  the  prophylaxis  and  treatment  of  post-operative
endophthalmitis. There are no reports of toxicity with single dose intraocular use to date. Multiple intravitreal injections
(mean  number  injections  was  6)  of  moxifloxacin  165  µg/0.1mL  combined  with  pegaptanib  (Macugen,  Valeant
Pharmacueticals, Montreal, QC) every 6 weeks as treatment for wet macular degeneration was well tolerated in 80 eyes
of 65 human patients during 13.2 months median follow-up [20].
Toxicity studies have not detected adverse effects during the 14 days following intravitreal injection of doses up to
160  µg  /0.1mL;  however,  a  dose  of  320  µg/0.1mL  led  to  marked  decreases  in  ERG  findings  in  rabbits  [21].
Concentrations higher than 150 µg/mL have adverse effects on primary retinal pigment epithelial cells in culture and
concentrations of 500 µg/mL led to occasional, isolated retinal necrosis in mice [22, 23].
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Phototoxicity  is  a  well-known  class  effect  of  fluoroquinolones  which  has  been  postulated  to  play  a  role  in  the
pathogenesis  of  iris  atrophy;  unlike  other  fluoreoquinolones,  phototoxicity  is  not  a  reported  adverse  effect  of  oral
moxifloxacin [2, 24]. Phototoxicity does not explain the selective involvement of iris pigment epithelium. The ciliary
body is also presumed to be involved given the loss of accommodation experienced by young individuals with BAIT
[10]. Retinal pigment epithelium does not demonstrate any abnormality on clinical examination. To our knowledge,
retinal electrophysiologic studies have not been performed on any affected individuals. Dermal phototoxicity has not
been reported as a feature of BAIT. The failure to determine serum moxifloxacin concentration at the time of aqueous
harvest is a weakness of this study.
Because the few PCR studies performed in patients previously afflicted with this condition were unrevealing, we
performed proteome analysis in an effort to further elucidate the pathogenesis of the condition [2, 10]. Interpretation of
results of proteomic analysis of the human eye in normal and disease states is limited by our incomplete, albeit rapidly
expanding, knowledge. The aqueous humor proteome of otherwise healthy patients undergoing cataract surgery was
initially reported to contain at least 54 unique proteins, comprised of albumin-bound, albumin-depleted fractions and 8
proteins common to both fractions [25]. A subsequent study of eyes undergoing cataract surgery identified 676 unique
aqueous proteins [26]. Depletion of albumin, the dominant protein identified in these samples, as well as fractionation
of the protein content of the aqueous humor would enhance the number of proteins identified in this experiment. The
authors speculate that not only would additional proteins be revealed by such processes, but additional peptides would
be identified—further increasing our confidence in the proteins identified. Due to the confounding level of albumin in
this data set, it is unclear whether moxifloxacin present in the aqueous resulted in the low spectral counts for one-third
of proteins identified. To our knowledge, there are not reports of aqueous proteome analysis in human idiopathic uveitis
and the lack of a patient with idiopathic uveitis serving as a control is a weakness of this study.
A second limitation of proteome analysis methods is that interpretation of shotgun proteomic data is hampered by
the so called ‘protein inference problem’; the same peptide sequence can be present in multiple different proteins or
isoforms leading to ambiguities in determining protein identity [27]. Proteome analysis did not aid in determining the
etiology of the condition but as methods continue to evolve, this technique may be a useful adjunct in ascertaining the
etiology of idiopathic ocular inflammatory conditions including BADI and BAIT.
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